Legal & General Group’s MoonLake Immunotherapeutics MLTX Stock Holding History

Legal & General Group’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$410K	Buy	21,044 +485	+2%	+$8.79K	﹤0.01%	2448
2026 Q1	$383K	Buy	20,559 +4,481	+28%	+$74.2K	﹤0.01%	2433
2025 Q4	$212K	Sell	16,078 -4,827	-23%	-$57K	﹤0.01%	2579
2025 Q3	$150K	Hold	20,905	–	–	﹤0.01%	2604
2025 Q2	$987K	Buy	20,905 +1,425	+7%	+$58K	﹤0.01%	2243
2025 Q1	$761K	Hold	19,480	–	–	﹤0.01%	2271
2024 Q4	$1.05M	Buy	19,480 +1,429	+8%	+$73K	﹤0.01%	2221
2024 Q3	$910K	Buy	18,051 +2,261	+14%	+$106K	﹤0.01%	2267
2024 Q2	$694K	Buy	+15,790	New	+$669K	﹤0.01%	2311

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Legal & General Group's MLTX Position: Q2 2026 in Review

Legal & General Group increased its MoonLake Immunotherapeutics (MLTX) stake by 2.4% in Q2 2026, buying an estimated $8.79K and bringing the position to 21,044 shares worth $410K. The position accounts for ﹤0.01% of the portfolio, ranked #2448.

Legal & General Group first reported a position in MLTX in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.05M in Q4 2024. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Legal & General Group held 21,044 shares of MoonLake Immunotherapeutics worth $410K as of Q2 2026.
Legal & General Group bought 485 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $8.79K.
MoonLake Immunotherapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2448 holding.
Legal & General Group first reported a position in MoonLake Immunotherapeutics in Q2 2024 and has held it in 9 quarters since.
Legal & General Group's MoonLake Immunotherapeutics position peaked at $1.05M in Q4 2024.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.